Investing.com - Financial Markets Worldwide
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Cellectis ramping up production capability for UCART123; shares ahead 12% premarket

Published 11/16/2016, 08:06 AM
Cellectis ramping up production capability for UCART123; shares ahead 12% premarket
CLLS
-
  • Cellectis (NASDAQ:CLLS) is up 12% premarket, albeit on only 600 shares, in response to its announcement that it successfully completed a series of large-scale production runs of TALEN gene edited product candidate UCART123, an engineered T-cell therapy candidate that targets CD123, an antigen found certain leukemic cells in acute myeloid leukemia (AML) as well as leukemic and other cancer cells in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The runs were performed under cGMP standards for the purpose of supplying product for two Phase 1 studies in AML and BPDCN patients.
  • The company says UCARTs are meant to be ready, off-the-shelf CAR T-cells that can be industrialized and standardized for a large patient population.
  • The company completed three GMP production runs of lead product candidate UCART19 in November 2015.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.